1. Home
  2. JCE vs ANL Comparison

JCE vs ANL Comparison

Compare JCE & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Core Equity Alpha Fund of Beneficial Interest

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

HOLD

Current Price

$14.81

Market Cap

247.6M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$6.82

Market Cap

293.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JCE
ANL
Founded
N/A
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
247.6M
293.4M
IPO Year
2007
2022

Fundamental Metrics

Financial Performance
Metric
JCE
ANL
Price
$14.81
$6.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
39.8K
168.9K
Earning Date
01-01-0001
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.51
$0.88
52 Week High
$16.31
$12.09

Technical Indicators

Market Signals
Indicator
JCE
ANL
Relative Strength Index (RSI) 44.34 41.53
Support Level $14.36 $1.36
Resistance Level $15.96 $9.98
Average True Range (ATR) 0.34 0.81
MACD -0.04 -0.18
Stochastic Oscillator 49.95 21.79

Price Performance

Historical Comparison
JCE
ANL

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: